Fortrea Holdings is trading 6.61% higher at $25.50 in pre-market, with no clear direct catalyst confirmed. - It closed at $23.92 on October 22. - On October 22, Fortrea announced a collaboration with Omico to advance biomarker-led oncology drug development in Australia; available information does not establish it as the cause of the move. - The broader market backdrop is negative, but the supplied context does not support attributing Fortrea’s rise to market sentiment.